Royal Bank of Canada’s Impact BioMedical IBO Stock Holding History

Royal Bank of Canada’s Portfolio IBO Stock Details IBO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$0	Hold	32	–	–	﹤0.01%	7830
2025 Q4	$0	Buy	32 +31	+3,100%	+$16	﹤0.01%	7766
2025 Q3	$0	Buy	+1	New	+$1	﹤0.01%	7626

Other funds holding IBO

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

VGA

Vanguard Global Advisers Malvern, Pennsylvania $187B AUM

MAC

Mason & Associates (California) Los Angeles, California $619M AUM 29.44% 1-Year Est. Return

Royal Bank of Canada's IBO Position: Q1 2026 in Review

Royal Bank of Canada held its Impact BioMedical (IBO) position steady in Q1 2026 at 32 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #7830.

Royal Bank of Canada first reported a position in IBO in Q3 2025 and has held it in 3 quarters since. 20 funds tracked by Wall St. Rank hold IBO as of Q1 2026.

Royal Bank of Canada held 32 shares of Impact BioMedical worth $0 as of Q1 2026.
Royal Bank of Canada left its Impact BioMedical share count unchanged in Q1 2026.
Impact BioMedical made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #7830 holding.
Royal Bank of Canada first reported a position in Impact BioMedical in Q3 2025 and has held it in 3 quarters since.
20 funds tracked by Wall St. Rank held Impact BioMedical as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.